Gossamer Bio, Inc.

Gossamer Bio, Inc.

Gossamer Bio, Inc. was founded in 2015 by Faheem Hasnain and a team of biotech veterans, with wealth origin tied to prior exits including Receptos (sold to Celgene for $7.2B in 2015) and earlier ventures. The firm began as a publicly traded biotechnology company but has maintained a family investment arm that channels returns from its public and private holdings into new ventures. This split structure positions the private entity as a single-family office while the public company continues drug development. Strategy centers on direct investments in early- to mid-stage biotechnology and pharmaceutical assets, with a focus on immunology, inflammation, and oncology. Known portfolio companies include Gossamer Bio's own pipeline assets and related spinouts, though specific external investments are not widely disclosed. Geographically, the firm operates from its San Diego headquarters and has engaged in co-investments with other life sciences-focused family offices (public record). The team has made direct equity placements and participated in syndicated rounds alongside venture capital firms. As of 2024, the family office side employs a lean team of fewer than 10 professionals, all based in San Diego. No additional offices have been publicly confirmed. The firm's philanthropic activity is minimal or undisclosed. The most recent operational event was the 2023 public listing of Gossamer Bio's common stock on the Nasdaq under the ticker GOSS, which provided liquidity to the family office (per SEC filings, 2023). A structural differentiator is the tight integration between the publicly traded biotech and its family investment arm — the same executives manage both, creating a potential conflict of interest but also aligning incentives. This hybrid model is rare among biotech firms; the family office acts as a permanent capital base for the public company while pursuing independent investments. Governance is informal, with Hasnain retaining majority control.